For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
The ins and outs, and ups and downs, of occupational asthma
The ins and outs, and ups and downs, of occupational asthma

Occupational health expert David McBride discusses the agents behind occupational asthma, including isocyanates used in the construction and painting industries
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Figley KD, Elrod RH. Endemic asthma due to castor bean dust. JAMA 1928;90(2):79–82.
2. Glass WI, Power P, Burt R, et al. Work-related respiratory symptoms and lung function in New Zealand mussel openers. Am J Ind Med 1998;34(2):163–68.
3. Neitzel JJ. Enzyme catalysis: The serine proteases. Nature Education 2010;3(9):21.
4. Pawlak M, Pobłocki K, Drzeżdżon J, et al. Isocyanates and isocyanides – life-threatening toxins or essential compounds? Sci Total Environ 2024;934:173250.
5. Redlich CA, Karol MH. Diisocyanate asthma: clinical aspects and immunopathogenesis. Int Immunopharmacol 2002;2(2-3):213–24.
6. Sabbioni G, Pugh SA. New method to biomonitor workers exposed to 1,6-hexamethylene diisocyanate. Chem Res Toxicol 2022;35(12):2285–95.
7. WorkSafe. Isocyanates WES Proposal to change. 7 May 2024.
8. New Zealand Paint Manufacturers Association Incorporated. Isocyanates. 2024.